Oura announced updates to its smart ring that will provide deeper insights into hormonal health, including effects of birth control and menopause symptoms. The features, starting rollout on May 6, allow users to log over 20 contraception combinations and track their impact on sleep, recovery, and temperature. The company is also partnering with Twentyeight Health for clinician access.
Oura, known for tracking sleep and health metrics, said Friday its rings will expand cycle insights to include hormonal birth control methods such as pills, patches, IUDs, and implants. Users who menstruate can log these to understand effects on biometrics like body temperature, sleep, and recovery, helping define normal cycles based on hormone and hormone-free days. The updates apply to Oura Ring Series 3 and 4, with global rollout beginning May 6, 2026, as confirmed by the company and reported by CNET on that date. Today's date is 2026-05-02, so the features remain scheduled for next week, with no changes indicated since the announcement. The new menopause insights feature includes a self-reported questionnaire assessing 22 symptoms' impact on mood, cognition, sleep, and daily functioning. Developed by Oura's clinical and science teams, it generates personalized results tied to biometric data for lifestyle guidance. Oura already offers a perimenopause assessment that produces shareable PDFs for doctors. Holly Shelton, Oura's chief product officer, stated, “When more than half of women in their reproductive years are using contraception and more than a billion women are moving through perimenopause and menopause, asking them to rely on trial and error, vague reassurance, or generic symptom trackers simply isn't good enough.” She added, “By connecting hormonal context to the biometric data Oura tracks, we're giving women visibility, language, and evidence they've never had at this scale.” Oura is partnering with Twentyeight Health to connect US members to licensed clinicians for same-day birth control consultations and prescriptions via the app. The company has existing ties with platforms like Maven Clinic and Midi Health. Privacy concerns persist post-2022 Dobbs decision, given risks of menstrual data in legal contexts, though Oura states it does not sell health data and processes AI insights on-device.
